Voltar
Revisão Acesso aberto Produção Nacional Revisado por pares
BIBTEX RIS

Renal Cell Carcinoma and Proteomics

2010; Karger Publishers; Volume: 84; Issue: 4 Linguagem: Inglês

10.1159/000296283

ISSN

1423-0399

Autores

Vanessa Sandim, Denise de Abreu Pereira, Antônio Augusto Ornellas, Gilda Alves,

Tópico(s)

Ubiquitin and proteasome pathways

Resumo

Renal cell carcinoma (RCC) represents 3% of adult malignancies. About 30% of RCC patients develop metastatic disease. So far, drugs cannot significantly increase the survival of these patients. We present a recent review of proteomics and RCC. Proteomic technologies have been used in the research to discover new markers of RCC that might increase survival. Furthermore, newly discovered markers cannot increase patient survival, rather their prognostic value supporting therapeutic decisions or new agents targeted at these new markers. More research is required to develop proteomic technologies and biomarkers for identification and validation.

Referência(s)